# Formula N-2331: Advanced Neuro-Cognitive Enhancement & Metabolic Support

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Multi-pathway neuro-regenerative and metabolic protocol â€“ enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **Dihexa** | 2 mg | HGF/c-Met System Activator; Potent Synaptogenic Agent |
| **Selank** | 0.3 mg | Tuftsin Analog; Anxiolytic; BDNF/NGF Modulator |
| **Semax** | 0.3 mg | ACTH(4-10) Analog; Nootropic; BDNF/NGF Upregulator |
| **NAD+ (Nicotinamide Adenine Dinucleotide)** | 100 mg | Essential Coenzyme; Sirtuin Activator; Redox Agent |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to protect peptide and coenzyme integrity from gastric degradation and ensure optimal absorption.

**Therapeutic Rationale & Intent:**
- Formula N-2331 is engineered to provide a comprehensive, four-pronged approach to cognitive enhancement by targeting **structural plasticity (Dihexa)**, **anxiety reduction (Selank)**, **neurotrophic support (Semax)**, and **fundamental cellular energy (NAD+)**.
- This formula is designed for individuals seeking to improve focus, memory, and mental clarity while simultaneously reducing anxiety and supporting long-term brain health and resilience against neurodegenerative processes.

---

## 2. Deep Mechanism of Action

Formula N-2331 integrates four synergistic components to create a powerful nootropic and neuroprotective stack that addresses brain health from the metabolic to the structural level.

### 2.1 Dihexa: Structural Synaptogenesis

Dihexa is a highly potent, orally active angiotensin IV analog that activates the Hepatocyte Growth Factor (HGF)/c-Met system, a critical pathway for neuronal growth, repair, and synaptogenesis [1]. By promoting the formation of new dendritic spines and synaptic connections, Dihexa physically increases the brain's capacity for learning and memory, providing a long-term structural foundation for cognitive enhancement.

### 2.2 Selank: Anxiolytic & Neurotrophic Support

Selank is a synthetic analog of the endogenous immunomodulatory peptide tuftsin. Its primary role is as a potent anxiolytic that reduces stress and anxiety without sedation by modulating the expression of genes involved in GABAergic neurotransmission [2]. Crucially, it also prevents the stress-induced decrease in Brain-Derived Neurotrophic Factor (BDNF) and increases its expression in the hippocampus, a key molecule for neuroplasticity and neuronal survival [3].

### 2.3 Semax: Nootropic & Neuroprotective Action

Semax is a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH). It is a well-researched nootropic that significantly increases the expression of both BDNF and Nerve Growth Factor (NGF) in key brain regions like the hippocampus and basal forebrain [4]. This powerful neurotrophic upregulation enhances attention, memory consolidation, and neuronal resilience against various insults, including hypoxia and oxidative stress.

### 2.4 NAD+: Fundamental Cellular Energy & Repair

Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in every cell, critical for mitochondrial energy production (ATP) via the electron transport chain. It is also the sole substrate for PARP enzymes (involved in DNA repair) and sirtuin deacetylases (master regulators of metabolism and longevity). Age-related decline in NAD+ levels is a key driver of neuronal dysfunction. Supplementing NAD+ provides neurons with the fundamental energy needed for demanding cognitive tasks and activates cellular repair and stress resistance pathways [5].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The power of N-2331 lies in its multi-level, synergistic design where each component supports and amplifies the others.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Metabolic (Power)** | Cellular Energy & Repair | **NAD+** provides the fundamental ATP energy required to fuel all other processes. It also activates sirtuins, which deacetylate and activate proteins involved in neuroprotection. | An energized and resilient cellular environment. Without sufficient NAD+, the brain cannot effectively build new connections or upregulate neurotrophic factors. |
| **Neurotrophic (Growth Signals)** | BDNF & NGF Upregulation | **Semax** provides a powerful, direct stimulus for BDNF and NGF production. **Selank** provides a secondary BDNF stimulus and, crucially, prevents stress from negating these gains. | A brain environment saturated with the growth factors necessary to support the survival of existing neurons and the growth and integration of new ones. |
| **Structural (Hardware)** | Synaptogenesis | **Dihexa**, fueled by NAD+ and stimulated by the BDNF/NGF from Semax and Selank, physically builds new dendritic spines and synapses. | A measurable increase in synaptic density and neural connectivity. The brain's hardware is upgraded, increasing its raw processing power and memory capacity. |
| **Functional (Software)** | Anxiolysis & Focus | **Selank** reduces the "noise" of anxiety, allowing for clearer cognitive processing. The enhanced connectivity from **Dihexa** and neurotrophic support from **Semax** improve signal transmission efficiency. | A state of calm, focused attention. The user is better able to utilize their enhanced cognitive hardware without the interference of stress or anxiety. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Days 1-3** | A noticeable reduction in anxiety and mental chatter. An initial increase in mental clarity and focus. Mood may feel more stable and resilient to stressors. | Selank begins to modulate GABAergic systems and stress pathways. Semax provides an initial boost to neurotrophin levels. |
| **Weeks 1-2** | More consistent cognitive enhancement. Improved memory recall, particularly for new information. Increased mental stamina for demanding tasks. | NAD+ levels begin to replete, improving mitochondrial function. The synergistic BDNF/NGF upregulation from Selank and Semax takes full effect. |
| **Months 1-3** | Significant improvements in overall cognitive function, mood, and stress resilience. Enhanced ability to learn new skills and concepts. | Dihexa-induced synaptogenesis leads to measurable changes in neural connectivity. The brain is operating at a higher level of efficiency. |
| **Months 3-6+** | Long-term consolidation of cognitive gains. A sustained state of calm focus becomes the new baseline. Enhanced brain health provides a buffer against future cognitive decline. | The brain's structure and neurochemical environment are fundamentally optimized for high performance and resilience. |

### 4.2 Clinical Monitoring Recommendations

- **Cognitive Testing:** Baseline and periodic testing with a validated cognitive assessment tool (e.g., Cambridge Brain Sciences) to objectively track improvements.
- **Psychological Assessment:** Use of validated anxiety scales (e.g., GAD-7) to track anxiolytic effects.
- **Metabolic Panel:** A baseline metabolic panel can be useful, as NAD+ plays a central role in metabolic health.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily, typically in the morning.
- **Timing:** Consistent daily use is recommended for optimal long-term neuro-regenerative benefits.
- **Optimization:** Can be cycled (e.g., 5 days on, 2 days off, or 3 months on, 1 month off) to maintain sensitivity and align with natural biological rhythms.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** Excellent safety profile. Selank and Semax have a long history of clinical use in Eastern Europe with no significant reported side effects. Dihexa and NAD+ are also very well-tolerated.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity to any component.
- **Tolerability:** Generally very well-tolerated. As with any nootropic, some users may experience mild, transient stimulation or headache upon initiation, which typically resolves with continued use or dose adjustment.

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **Stimulants** (e.g., Amphetamine, Methylphenidate) | Semax, Selank | **Low to Moderate Risk.** Potential for additive focusing effects. May allow for a reduction in stimulant dosage. Use with caution and monitor for overstimulation. |
| **Anxiolytics** (e.g., Benzodiazepines) | Selank | **Low Risk.** May have additive anxiolytic effects, potentially allowing for a reduction in benzodiazepine dosage under medical supervision. |
| **Antidepressants** (SSRIs, SNRIs) | Selank, Semax | **Low Risk.** Generally well-tolerated. The anxiolytic and neurotrophic effects may be complementary to antidepressant therapy. Monitor mood as usual. |
| **Cancer Therapies** | NAD+ | **Theoretical Risk.** Some cancer cells have high NAD+ requirements. While evidence is mixed, it is prudent to avoid high-dose NAD+ supplementation during active cancer treatment unless cleared by an oncologist. |

---

## 6. References

[1] Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. *Brain Sciences*, 11(11), 1487. doi:10.3390/brainsci11111487

[2] Volkova, A., et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. *Frontiers in Pharmacology*, 7, 31. doi:10.3389/fphar.2016.00031

[3] Inozemtseva, L. S., et al. (2008). Anxiolytic effect of Semax and Selank in studied on rodents. *Zhurnal Vysshei Nervnoi Deiatelnosti Imeni I P Pavlova*, 58(4), 475-484. PMID: 18756821

[4] Dolotov, O. V., et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. *Brain Research*, 1117(1), 54-60. doi:10.1016/j.brainres.2006.07.115

[5] Braidy, N., et al. (2011). NAD+ as a metabolic regulator of transcription, longevity and disease. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1810(7), 684-693. doi:10.1016/j.bbagen.2011.04.004
